

PATENT ASSIGNMENT COVER SHEET

Electronic Version v1.1
 Stylesheet Version v1.2

EPAS ID: PAT5998040

SUBMISSION TYPE:	NEW ASSIGNMENT	
NATURE OF CONVEYANCE:	ASSIGNMENT	
CONVEYING PARTY DATA		
	Name	Execution Date
	MACROPLATA, INC.	11/01/2016
RECEIVING PARTY DATA		
Name:	LUMENR, LLC.	
Street Address:	253 MAIN STREET	
Internal Address:	SUITE 270	
City:	MATAWAN	
State/Country:	NEW JERSEY	
Postal Code:	07747	
PROPERTY NUMBERS Total: 1		
	Property Type	Number
	Application Number:	16789967
CORRESPONDENCE DATA		
Fax Number:		
<i>Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent using a fax number, if provided; if that is unsuccessful, it will be sent via US Mail.</i>		
Email:	rmoye@kdbfirm.com	
Correspondent Name:	KACVINSKY DAISAK BLUNI PLLC	
Address Line 1:	2601 WESTON PARKWAY	
Address Line 2:	SUITE 103	
Address Line 4:	CARY, NORTH CAROLINA 27513	
ATTORNEY DOCKET NUMBER:	8150.0478C6	
NAME OF SUBMITTER:	RODDY MOYE	
SIGNATURE:	/Roddy Moye/	
DATE SIGNED:	03/05/2020	
Total Attachments: 18		
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page1.tif		
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page2.tif		
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page3.tif		
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page4.tif		
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page5.tif		

source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page6.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page7.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page8.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page9.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page10.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page11.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page12.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page13.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page14.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page15.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page16.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page17.tif
source=Macroplata to LumenR - Assignment of IP (Execution Version)(71472679_9_US-DOCS)#page18.tif

INTELLECTUAL PROPERTY ASSIGNMENT AGREEMENT

This Intellectual Property Assignment Agreement (“**Agreement**”) is entered into on November 1, 2016 by and among:

Macroplata, Inc., a company duly incorporated under the laws of the State of Delaware, having its registered office at 113 Laredo Drive, Morganville, New Jersey 07751, USA (hereinafter referred to as “**Macroplata**”),

and

Macroplata Systems, LLC, a New Jersey corporation having a place of business at 113 Laredo Drive, Morganville, New Jersey 07751 (hereinafter referred to as “**MPSL**”),

and

LumenR, LLC, a Delaware limited liability company having an address at 253 Main Street, Suite 270, Matawan, NJ 07747 (hereinafter referred to as “**LumenR**”).

Macroplata, MPSL, and LumenR are hereinafter also referred to individually as a “**Party**” and collectively as “**the Parties**.”

WHEREAS, Macroplata owns the Macroplata Patents and Intellectual Property (defined below);

WHEREAS, certain entities, including MPSL, confirmed Macroplata’s ownership of the Macroplata Patents and Intellectual Property (defined below) in a Confirmatory Assignment of Patent Rights, dated March 4, 2014;

WHEREAS, Macroplata and MPSL are each substantially owned and controlled by Gregory Piskun (“**Piskun**”) who is the majority owner of LumenR;

WHEREAS, MPSL and LumenR are Parties to a License and Assignment of Rights Agreement, dated February 20, 2009;

WHEREAS, MPSL and LumenR wish to terminate the License and Assignment of Rights Agreement, dated February 20, 2009 (defined and identified below);

WHEREAS, LumenR wishes to acquire the Macroplata Patents and Intellectual Property, and Macroplata is willing to transfer the same to LumenR on the conditions set forth herein;

WHEREAS, LumenR and Boston Scientific Corporation, a Delaware corporation (“**Boston Scientific**”), are parties to that certain Asset Purchase Agreement dated as of the date hereof (as amended and in effect from time to time, the “**Purchase Agreement**”);

WHEREAS, it is a condition precedent to Boston Scientific purchasing the Acquired Assets (as defined in the Purchase Agreement) from LumenR under the Purchase Agreement that the Parties hereto execute and deliver this Agreement in favor of LumenR; and

WHEREAS, Piskun, will receive significant consideration in connection with the consummation of the transactions contemplated by the Purchase Agreement;

NOW, THEREFORE, in consideration of the mutual obligations and covenants contained herein and such other good and valuable consideration the receipt and sufficiency of which are hereby acknowledged, the Parties have agreed as follows:

1. **Definitions.** The following terms when used in this Agreement shall have the respective meanings ascribed thereto below:

1.1 **"Affiliate(s)"** shall mean, with respect to any Person, (a) any other Person directly or indirectly controlling, controlled by, or under common control with, such Person, (b) any member of the immediate family (including spouse, brother, sister, descendant, ancestor or in-law) of any officer, director or ten percent (10%) or greater equity holder of such Person, or (c) any entity in which such Person or any such family member has a ten percent (10%) or greater interest or is a director, officer, partner or trustee; provided that, for the purposes of this definition, "control" (including, with correlative meanings, the terms "controlled by" and "under common control with"), as used with respect to any Person, shall mean the possession, directly or indirectly, of the power to direct or cause the direction of the management and policies of such Person, whether through the ownership of voting securities, by contract or otherwise.

1.2 **"Intellectual Property"** shall mean all worldwide intellectual property or proprietary rights of any description including:

(a) all United States and foreign issued patents, reissued or re-examined patents, revivals of patents, utility models, certificates of invention, registrations of patents and renewals and extensions thereof, regardless of country issued or formal name (collectively, **"Issued Patents"**);

(b) all United States and foreign published or unpublished non-provisional and provisional patent applications, reissue applications, re-examination proceedings, invention disclosures and records of invention, continuations, continuations-in-part, requests for continued examination and divisions, regardless of country filed or formal name (collectively **"Patent Applications"** and, with the Issued Patents, the **"Patents"**);

(c) all copyrights, copyrightable works, semiconductor topography and mask work rights, including all rights of authorship, use, publication, reproduction, distribution, performance transformation, moral rights and rights of ownership of copyrightable works, semiconductor topography works and mask works, and all applications and registrations for the same and all rights to register and obtain renewals and extensions of registrations, together with all other interests accruing by reason of international copyright, semiconductor topography and mask work conventions (collectively, **"Copyrights"**);

(d) all trademarks, registered trademarks, applications for registration of trademarks, service marks, registered service marks, applications for registration of service marks, common law trademarks, trade names, registered trade names and applications for registrations of trade names and domain name registrations (collectively, “**Trademarks**”);

(e) all technology, ideas, inventions, discoveries, improvements, modifications, methodologies, schematics, business methods, drawings, designs, prototypes, models, confidential and proprietary information, Trade Secrets, manufacturing and operating specifications, methods of manufacturing, know-how, formulae, technical data, computer programs, hardware, software and processes, customer and supplier lists, whether or not patentable;

(f) all rights in databases and data collections;

(g) all other intangible assets, properties and rights (whether or not appropriate steps have been taken to protect, under applicable law, such other intangible assets, properties or rights); and

(h) all goodwill related to any of the foregoing.

1.3 “**License and Assignment of Rights Agreement**” shall mean the License and Assignment of Rights Agreement entered between Macroplata Systems LLC and LumenR, LLC on February 20, 2009, and all amendments and iterations thereof.

1.4 “**Macroplata Patents and Intellectual Property**” shall mean (a) the Issued Patents and Patent Applications identified in Appendix A, as well as any patents or patent applications claiming priority to such Issued Patents or Patent Applications; (b) know-how and Trade Secrets relating to the Issued Patents and Patent Applications identified in Appendix A; (c) any information or rights necessary to practice the Issued Patents or Patent Applications identified in Appendix A; (d) the Trademarks identified on Appendix A and all goodwill symbolized thereby or associated therewith; and (e) all other Intellectual Property owned or licensed by Macroplata or MPSL in connection with or related to the Products, or otherwise used in or useful to the sale, use, manufacture or commercialization of the Products, all licenses and sublicenses granted or obtained with respect thereto and rights thereunder, and other agreements with respect to the foregoing including but not limited to that certain Patent and Technology Purchase Agreement among Macroplata, MPSL and HET Systems, LLC dated March 4, 2014, all remedies against infringements thereof, rights to protection of interests therein, all income, royalties and payments receivable in respect thereof, and all claims, causes of action, choses in action, rights of recovery and rights of set-off of any kind with respect thereto (including all damages and payments for past, present or future infringement or misappropriation or dilution of the foregoing, the right to sue and recover for past, present or future infringements or misappropriations or dilutions of the foregoing), and any and all corresponding rights that have been or now or hereafter may be secured throughout the world with respect to any of the foregoing.

1.5 “**Person**” means an individual, corporation, partnership, limited partnership, limited liability company, syndicate, person (including a “person” as defined in Section 13(d)(3)

of the Securities Exchange Act of 1934, as amended), trust, association or entity or government, political subdivision, agency or instrumentality of a government.

1.6 **“Product(s)”** shall mean any device, instrument, diagnostic, therapeutic, product, system or process, and application, methods, or service (a) covered or described by the Issued Patents or Patent Applications set forth on Appendix A; or (b) related to the LumenR Retractor System product for partial or full thickness resections in the rectum, colon, esophagus or stomach comprising an endoscopic overtube with expandable distal end; or (c) related to procedures in the rectum, colon, esophagus or stomach, excluding procedures for treatment of hemorrhoids and prolapsed rectum.

1.7 **“Third Party”** shall mean any entity other than a Party or an Affiliate of a Party.

1.8 **“Trade Secret”** shall mean information and know-how to the extent that such information or know-how (a) derives independent economic value, actual or potential, from not being generally known to the public or to other persons who can obtain economic value from its disclosure or use and (b) is the subject of efforts that are reasonable under the circumstances to maintain its secrecy. Trade Secrets may include, but is not limited to confidential information, know-how, processes, schematics, business methods, formulae, drawings, prototypes, models, designs, customer lists and supplier lists that meet the foregoing definition.

2. **Transfer of Rights**

2.1 **Purchased Macroplata Patents And Intellectual Property**

Subject to the terms and conditions of this Agreement, Macroplata and MPSL hereby irrevocably and unconditionally assigns and transfers to LumenR all right, title and interest in the Macroplata Patents and Intellectual Property, free and clear of all liens, charges, security interests and encumbrances.

3. **Termination of Prior Agreement**

The Parties hereby terminate the License and Assignment of Rights Agreement pursuant to Article 8 of such License and Assignment of Rights Agreement. This Agreement is intended to supersede all rights and obligations contained within the License and Assignment of Rights Agreement.

4. **Further Assurances**

Each of Macroplata and MPSL agrees to assist and cooperate in a reasonable manner in obtaining protection for, enforcing, and perfecting title in the Macroplata Patents and Intellectual Property in LumenR (including joining as a party to any action if Macroplata or MPSL is deemed to be a necessary party thereto). Macroplata shall duly execute and deliver to LumenR an Assignment of Patents and Patent Applications in the form attached hereto as Appendix B and such other documents as LumenR may reasonably request to effect the transactions contemplated hereby, (including without limitation all instruments of assignment and transfer with respect to the Macroplata Patents and Intellectual Property as LumenR may reasonably request and as may be necessary to vest in LumenR good and marketable title to all

of Macroplata Patents and Intellectual Property, in each case free of all liens, charges, security interests or encumbrances).

5. Representations, Warranties and Covenants

5.1 Each of Macroplata and MPSL represents and warrants that, prior to giving effect to the transactions contemplated hereby and by the Asset Purchase Agreement, dated on or about the date hereof, by and between LumenR and Boston Scientific Corporation:

5.1.1 Macroplata is the sole owner of the Macroplata Patents and Intellectual Property and Macroplata has good and marketable title thereto. None of the Macroplata Patents and Intellectual Property is subject to any lien, charge, security interest or other encumbrance.

5.1.2 Macroplata and MPSL each has the full and unrestricted right and necessary power and authority to entry into, execute and deliver this Agreement, grant the rights granted herein and consummate the transactions contemplated hereby.

5.1.3 The entry into, execution and delivery by Macroplata and MPSL of this Agreement or any other instrument or document required by this Agreement do not, and the performance of this Agreement, including, without limitation, the granting of licenses granted hereunder, will not, (a) conflict with or violate the organizational documents of Macroplata or MPSL, (b) conflict with or violate any law, order or regulation applicable to Macroplata or MPSL, or (c) result in any breach or violation of or constitute a material default under, or give to others any rights of termination, amendment, acceleration or cancellation of, or result in the creation of a lien, charge, security interest or encumbrance in favor of any Third Party on the Macroplata Patents and Intellectual Property.

5.1.4 Neither Macroplata nor MPSL has granted any right, license, or interest in, to or under the Macroplata Patents and Intellectual Property inconsistent with the rights granted to LumenR in this Agreement.

5.1.5 No invalidity proceedings are pending in relation to any of the Macroplata Patents and Intellectual Property, and no such proceedings have been threatened orally or in writing.

5.1.6 Neither Macroplata nor MPSL has knowledge of intellectual property or conduct that it believes could reasonably render the Macroplata Patents and Intellectual Property invalid or unenforceable.

5.1.7 Neither Macroplata nor MPSL has knowledge of any issued patents or pending patent applications owned by Third Parties that would be infringed by LumenR's practice of the Macroplata Patents and Intellectual Property.

5.1.8 Neither Macroplata nor MPSL has knowledge of a Third Party due any consideration as a result of this Agreement or the transactions contemplated hereby.

5.1.9 No additional consents of, or notice to, any Third Party is required for Macroplata or MPSL to execute and deliver this Agreement.

6. Miscellaneous

6.1 Non-Derogation of Macroplata Patents and Intellectual Property. Macroplata and MPSL each covenant not to directly or indirectly take any action that may negatively impact the value, validity, or enforceability of the Macroplata Patents and Intellectual Property, including challenging or inducing any third party to challenge the validity or enforceability of the Macroplata Patents and Intellectual Property, or any patent claim(s) therein, or initiate or participate in any re-examination or other proceeding related to the validity, enforceability or patentability of any claim of the Macroplata Patents and Intellectual Property before any tribunal or patent office.

6.2 Entire Understanding. This Agreement and any attachments hereto constitute a single, integrated written contract expressing the entire agreement of the Parties with respect to the subject matter hereof and shall not be modified, supplemented, or repealed except by a writing signed by each of the Parties. No covenants, agreements, representations, or warranties of any kind whatsoever have been made by any Party, except as specifically set forth in this Agreement. All prior discussions, written communications, agreements, including the License and Assignment of Rights Agreement, and negotiations with respect to the subject matter hereof have been merged and integrated into and are superseded by this Agreement.

6.3 Assignment. This Agreement will be binding upon and inure to the benefit of the Parties hereto and their respective successors and assigns, each of which such successors and assigns will be deemed to be a party hereto for all purposes hereof. This Agreement shall not be assigned by any Party except that any Party may assign all or any of its rights and obligations hereunder, to an Affiliate of such Party, or to a Person that acquires all of the capital stock or all or substantially all of the assets or business of such Party to which this Agreement relates.

6.4 Governing Law. This Agreement shall be governed by and construed in accordance with the Laws of the State of Delaware, without regard to the conflicts of law principles of such State.

6.5 Authority; Due Execution. Each Party represents and warrants to the other, that (a) it has full power and authority to enter into this Agreement and any agreements related hereto and, subject to the terms and conditions hereof, this Agreement, when executed, will be a valid and legally binding obligation of such Party according to its provisions; (b) the execution and performance of this Agreement will not constitute a breach of or an event of default under any agreement, contract, law or regulation to which such Party is or may be bound; and (c) the execution and performance of this Agreement has been duly authorized by all necessary corporate action.

6.6 Third-Party Beneficiary. For the avoidance of doubt, Boston Scientific shall be an intended third-party beneficiary of this Agreement and shall be entitled to enforce directly the assignments and transfers contained herein and the ongoing obligations of the Parties hereunder.

[Signature Pages Follow]

AS WITNESS, the Parties have caused this Agreement to be signed on the date first written above.

AS WITNESS, the Parties have caused this Agreement to be signed on the date first written above.

Macroplata, Inc.

By: G. Piskun

Name: Gregory Piskun, M.D.

Title: President

Macroplata Systems, LLC

By: G. Piskun

Name: Gregory Piskun, M.D.

Title: President

LumenR, LLC

By: G. Piskun

Name: Gregory Piskun, M.D.

Title: Chief Executive Officer

APPENDIX A
Issued Patents and Patent Applications

The Issued Patents and Patent Applications referred to in Section 1.4 of the Intellectual Property Assignment Agreement, dated November 1, 2016, shall include:

U.S. Filings	
Serial/Publication No.	Filing Date
U.S. Patent No. 9,039,601	August 25, 2009
U.S. Application No. 14/511,694 (U.S. Publication No. 2015-0045616)	October 10, 2014
U.S. Application No. 15/168,083	May 29, 2016
U.S. Patent No. 8,506,479	December 16, 2010
U.S. Patent No. 9,161,746	December 23, 2012
U.S. Application No. 14/732,749 (U.S. Publication No. 2015/0265818)	June 7, 2015
U.S. Application No. 14/738,863 (U.S. Publication No. 2015/0313584)	June 13, 2015
U.S. Application No. 15/173,455 (U.S. Publication No. 2011/0288538)	June 3, 2016
U.S. Application No. 14/866,695 (U.S. Publication No. 2016/0015252)	September 25, 2015
U.S. Patent No. 8,932,211	June 22, 2012
U.S. Patent No. 9,125,636	April 12, 2013
U.S. Patent No. 9,186,130	April 12, 2013
U.S. Application No. 14/506,666 (U.S. Publication No. 2015/0025314)	October 5, 2014
U.S. Application No. 15/230,455	August 7, 2016
U.S. Application No. 14/696,421 (U.S. Publication No. 2015/0223798)	April 25, 2015
U.S. Application No. 14/815,985 (U.S. Publication No. 2015/0335324)	August 1, 2015
U.S. Application No. 14/929,214 (U.S. Publication No. 2016/0051128)	October 30, 2015
U.S. Patent No. 9,186,131	June 9, 2013
U.S. Application No. 14/678,949 (U.S. Publication No. 2015-0209024)	April 4, 2015
U.S. Application No. 14/745,396 (U.S. Publication No. 2015/0282800)	June 20, 2015
U.S. Application No. 14/752,908 (U.S. Publication No. 2015/0297209)	June 27, 2015
U.S. Application No. 15/201,398	July 2, 2016
U.S. Application No. 14/099,943 (U.S. Publication No. 2014/0142393)	December 7, 2013

U.S. Application No. 14/622,831 (U.S. Publication No. 2015-0157192)	February 14, 2015
U.S. Application No. 14/714,287 (U.S. Publication No. 2015/0272564)	May 16, 2015
U.S. Application No. 15/148,999	May 16, 2016
U.S. Application No. 15/261,930	September 10 2016

Foreign Filings	
Serial/Publication No.	Filing Date
Canadian Publication No. 2,783,252	June 6, 2012
Chinese Publication No. 2010/80057201.5	June 15, 2012
European Publication No. 10842611.5	July 26, 2012
Korean Publication No. 10-2012- 701840	July 13, 2012
Japanese Publication No.: 2012/544833 Japanese Patent No. 5,852,008	June 11, 2012
Australian Publication No. 2013/277448	December 18, 2014
Canadian Publication No. 2,883,783	December 16, 2014
Chinese Publication No. 2013/80033096.5	December 22, 2014
European Publication No. 13735103.7	January 15, 2015
Japanese Publication No. 2015/518501	December 15, 2014
Korean Publication No. 10-2015- 7001534	January 20, 2015
Australian Publication No. 2014278600	December 18, 2015
Canadian Publication No. 2,915,935	November 17, 2015
Chinese Publication No. 201480032680.3	December 8, 2015
European Publication No. 14733912.1	January 6, 2016
Japanese Publication No. 2016-518367	December 8, 2015
Korean Publication No. 10-2016- 7000338	January 7, 2016
PCT Publication No 2016/16911	February 16, 2016
PCT Publication No. 2016/31355	May 16, 2016

APPENDIX B
Assignment of Patents and Patent Applications

ASSIGNMENT OF PATENTS AND PATENT APPLICATIONS

This Assignment of Patents and Patent Applications is made as of the 1st day of November, 2016 (this "Assignment") by Macroplata, Inc., a Delaware corporation ("Macroplata Inc."), Macroplata Systems, LLC ("MPSL" and, together with Macroplata Inc., "Assignors") in favor of LumenR LLC, a Delaware limited liability company ("Assignee"). Capitalized terms used and not otherwise defined herein shall have the meanings ascribed to them in that certain Asset Purchase Agreement dated as of November 1, 2016 (the "Purchase Agreement"), by and between Assignee and the party named as Buyer therein.

WHEREAS, Assignors are the owners of certain patents and patent applications in the United States Patent and Trademark Office and other foreign offices identified in Exhibit 1 attached hereto (the "Assigned Patent Rights");

WHEREAS, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, Assignors desire to sell, transfer, assign and set over unto Assignee all right, title and interest of Assignors in and to the Assigned Patent Rights, pursuant to the terms of the Purchase Agreement;

WHEREAS, pursuant to the terms of the Purchase Agreement, Assignee has agreed to execute and deliver all documents as the Buyer may reasonably request of Assignee to effect the transactions contemplated by the Purchase Agreement, including all instruments of assignment and transfer with respect to the Assigned Patent Rights; and

NOW, THEREFORE, for good and valuable consideration, including the representations, warranties, covenants and agreements contained in the Purchase Agreement, the receipt and sufficiency of which are hereby acknowledged, Assignor does hereby sell, assign, transfer and set over unto Assignee, its successors and assigns, the entire and exclusive right, title and interest in and to the Assigned Patent Rights, including all inventions in the United States and throughout the world described therein, and the applications and patents issuing from applications listed therein, and any applications and patents claiming priority to any of those listed therein, and any applications and patents from which those listed therein may claim priority to, and any other continuations-in-part, divisionals, reissues, extensions and foreign counterparts of the Assigned Patent Rights, together with all claims for damages by reason of past, present or future infringement of any Assigned Patent Rights, with the right to sue for and collect the same, and any and all other corresponding rights that have been, or hereafter may be, secured throughout the world with respect to the Assigned Patent Rights. Assignor further agrees to execute and has executed all documents, instruments and papers and to perform all acts, without any further consideration, as reasonably requested by Assignee, its successors and assigns, to perfect in Assignee, its successors and assigns, the foregoing rights, title and interests, including the execution of any related domestic or foreign application documents.

Assignor hereby authorizes and requests the Director of the United States Patent and Trademark Office (and its foreign counterparts in any applicable jurisdiction) to issue the Patents resulting from the applications in the Assigned Patent Rights to Assignee, its successors and assigns.

This Assignment is subject in all respects to the terms and conditions of the Purchase Agreement, which are incorporated herein by reference. This Assignment is given to further evidence (and give immediate effect to) the transfers and assignments contemplated by the Purchase Agreement upon the terms and conditions specified therein. Nothing contained in this Assignment

shall in any way supersede, modify, replace, amend, change, rescind, waive, exceed, expand, reduce, enlarge or in any way affect the provisions, including warranties, covenants, agreements, conditions, representations or, in general, any of the rights and remedies, and any of the obligations, of any party to the Purchase Agreement set forth therein. In the event of any conflict or inconsistency between the terms of the Purchase Agreement and the terms hereof, the terms of the Purchase Agreement will govern.

This Assignment shall be governed by, and construed in accordance with the laws of the State of Delaware, United States, without regard to conflicts of law principles.

This Assignment may be executed in multiple counterparts, each of which will be deemed an original, but all such counterparts taken together will constitute one and the same Assignment. Copies of executed signature pages delivered by facsimile or other electronic means (*i.e.*, .pdf or .tif) shall be deemed originals.

[Signature Pages Follow]

IN WITNESS WHEREOF, Assignors have executed this Assignment as an instrument under seal effective as of this 1st day of November, 2016.

MACROPLATA, INC.

MACROPLATA SYSTEMS, LLC

By: _____
Name:
Title:

By: _____
Name:
Title:

STATE OF _____
COUNTY OF _____

On this the _____ day of _____, 2016, before me appeared _____, the person who signed this instrument, who acknowledged that he signed such instrument as his free act and deed.

Notary Public

My commission expires: _____

IN WITNESS WHEREOF, Assignee has executed this Assignment as an instrument under seal effective as of this 1st day of November, 2016.

LUMENR LLC

By: _____

Name:

Title:

[SIGNATURE PAGE TO ASSIGNMENT OF PATENTS AND PATENT APPLICATIONS]

EXHIBIT 1**Patent Rights**

U.S. Filings		
Serial/Publication No.	Filing Date	Title
U.S. Patent No. 9,039,601	August 25, 2009	Endoluminal treatment method and associated surgical assembly including tissue occlusion device
U.S. Application No. 14/511,694 (U.S. Publication No. 2015-0045616)	October 10, 2014	ENDOLUMINAL TREATMENT METHOD AND ASSOCIATED SURGICAL ASSEMBLY
U.S. Application No. 15/168,083	May 29, 2016	ENDOLUMINAL TREATMENT METHOD AND ASSOCIATED SURGICAL ASSEMBLY
U.S. Patent No. 8,506,479	December 16, 2010	Substantially rigid and stable endoluminal surgical suite for treating a gastrointestinal lesion
U.S. Patent No. 9,161,746	December 23, 2012	Substantially rigid and stable endoluminal surgical suite for treating a gastrointestinal lesion
U.S. Application No. 14/732,749 (U.S. Publication No. 2015/0265818)	June 7, 2015	SUBSTANTIALLY RIGID AND STABLE ENDOLUMINAL SURGICAL SUITE FOR TREATING A GASTROINTESTINAL LESION
U.S. Application No. 14/738,863 (U.S. Publication No. 2015/0313584)	June 13, 2015	SUSTANTIALLY RIGID AND STABLE ENDOLUMINAL SURGICAL SUITE FOR TREATING A GASTROINTESTINAL LESION
U.S. Application No. 15/173,455 (U.S. Publication No. 2011/0288538)	June 3, 2016	APPARATUS AND METHOD FOR EFFECTING AT LEAST ONE ANATOMICAL STRUCTURE
U.S. Application No. 14/866,695 (U.S. Publication No. 2016/0015252)	September 25, 2015	SUBSTANTIALLY RIGID AND STABLE ENDOLUMINAL SURGICAL SUITE FOR TREATING A GASTROINTESTINAL LESION
U.S. Patent No. 8,932,211	June 22, 2012	Floating, multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
U.S. Patent No. 9,125,636	April 12, 2013	Endoluminal device with retractor system
U.S. Patent No. 9,186,130	April 12, 2013	Endoluminal system for gastrointestinal treatment
U.S. Application No. 14/506,666 (U.S. Publication No. 2015/0025314)	October 5, 2014	ENDOLUMINAL SYSTEM AND METHOD FOR GASTROINTESTINAL TREATMENT
U.S. Application No. 15/230,455	August 7, 2016	FLOATING, MULTI-LUMEN-CATHETER RETRACTOR SYSTEM FOR A MINIMALLY-INVASIVE,

		OPERATIVE GASTROINTESTINAL TREATMENT
U.S. Application No. 14/696,421 (U.S. Publication No. 2015/0223798)	April 25, 2015	FLOATING, MULTI-LUMEN-CATHETER RETRACTOR SYSTEM FOR A MINIMALLY-INVASIVE, OPERATIVE GASTROINTESTINAL TREATMENT
U.S. Application No. 14/815,985 (U.S. Publication No. 2015/0335324)	August 1, 2015	ENDOLUMINAL DEVICE WITH RETRACTOR SYSTEM
U.S. Application No. 14/929,214 (U.S. Publication No. 2016/0051128)	October 30, 2015	ENDOLUMINAL SYSTEM FOR GASTROINTESTINAL TREATMENT
U.S. Patent No. 9,186,131	June 9, 2013	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
U.S. Application No. 14/678,949 (U.S. Publication No. 2015-0209024)	April 4, 2015	MULTI-LUMEN-CATHETER RETRACTOR SYSTEM FOR A MINIMALLY-INVASIVE, OPERATIVE GASTROINTESTINAL TREATMENT
U.S. Application No. 14/745,396 (U.S. Publication No. 2015/0282800)	June 20, 2015	FLOATING, MULTI-LUMEN-CATHETER RETRACTOR SYSTEM FOR A MINIMALLY-INVASIVE, OPERATIVE GASTROINTESTINAL TREATMENT
U.S. Application No. 14/752,908 (U.S. Publication No. 2015/0297209)	June 27, 2015	FLOATING, MULTI-LUMEN-CATHETER RETRACTOR SYSTEM FOR A MINIMALLY INVASIVE, OPERATIVE GASTROINTESTINAL TREATMENT
U.S. Application No. 15/201,398	July 2, 2016	MULTI-LUMEN-CATHETER RETRACTOR SYSTEM FOR A MINIMALLY-INVASIVE, OPERATIVE GASTROINTESTINAL TREATMENT
U.S. Application No. 14/099,943 (U.S. Publication No. 2014/0142393)	December 7, 2013	MULTI-LUMEN-CATHETER RETRACTOR SYSTEM FOR A MINIMALLY-INVASIVE, OPERATIVE GASTROINTESTINAL TREATMENT
U.S. Application No. 14/622,831 (U.S. Publication No. 2015-0157192)	February 14, 2015	SYSTEM FOR A MINIMALLY-INVASIVE, OPERATIVE GASTROINTESTINAL TREATMENT
U.S. Application No. 14/714,287 (U.S. Publication No. 2015/0272564)	May 16, 2015	TISSUE RETRACTOR FOR MINIMALLY INVASIVE SURGERY
U.S. Application No. 15/148,999	May 16, 2016	TISSUE RETRACTOR FOR MINIMALLY INVASIVE SURGERY
U.S. Application No. 15/261,930	September 10 2016	SYSTEM FOR A MINIMALLY-

		INVASIVE, OPERATIVE GASTROINTESTINAL TREATMENT
--	--	---

Foreign Patents		
Publication No.	Filing Date	Title of Invention
Canadian Publication No. 2,783,252	June 6, 2012	Arrangements and methods for effecting an endoluminal anatomical structure
Chinese Publication No. 2010/80057201.5	June 15, 2012	Arrangements and methods for effecting an endoluminal anatomical structure
European Publication No. 10842611.5	July 26, 2012	Arrangements and methods for effecting an endoluminal anatomical structure
Korean Publication No. 10-2012-701840	July 13, 2012	Arrangements and methods for effecting an endoluminal anatomical structure
Japanese Publication No.: 2012/544833 Japanese Patent No. 5,852,008	June 11, 2012	Arrangements and methods for effecting an endoluminal anatomical structure
Australian Publication No. 2013/277448	December 18, 2014	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
Canadian Publication No. 2,883,783	December 16, 2014	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
Chinese Publication No. 2013/80033096.5	December 22, 2014	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
European Publication No. 13735103.7	January 15, 2015	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
Japanese Publication No. 2015/518501	December 15, 2014	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
Korean Publication No. 10-2015-7001534	January 20, 2015	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
Australian Publication No. 2014278600	December 18, 2015	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
Canadian Publication No. 2,915,935	November 17, 2015	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment

Chinese Publication No. 201480032680.3	December 8, 2015	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
European Publication No. 14733912.1	January 6, 2016	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
Japanese Publication No.	December 8, 2015	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
Korean Publication No. 10-2016-7000338	January 7, 2016	Multi-lumen-catheter retractor system for a minimally-invasive, operative gastrointestinal treatment
PCT Publication No 2016/16911	February 16, 2016	System for a minimally-invasive, operative gastrointestinal treatment
PCT Publication No. 2016/31355	May 16, 2016	Tissue retractor for minimally invasive surgery